Compare BGY & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGY | DCTH |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.1M | 578.4M |
| IPO Year | N/A | 2015 |
| Metric | BGY | DCTH |
|---|---|---|
| Price | $5.39 | $14.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 314.4K | 248.2K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 7.41% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | N/A | $24.27 |
| P/E Ratio | ★ N/A | $362.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $8.12 |
| 52 Week High | $6.23 | $17.42 |
| Indicator | BGY | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 45.82 |
| Support Level | $5.19 | $14.52 |
| Resistance Level | $5.85 | $16.51 |
| Average True Range (ATR) | 0.08 | 0.48 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 19.57 | 45.76 |
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.